ClinicalTrials.gg
CompletedNCT03556358Updated Jan 14, 2022Results posted

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

A Phase 3 interventional study of TX05 (trastuzumab) and Herceptin® in Breast Cancer, Breast Neoplasms and HER2-positive Breast Cancer, sponsored by Tanvex BioPharma USA, Inc.. Completed at 146 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by Tanvex BioPharma USA, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
809
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
23rd of 366
809 · median 61
Started
2018
with 7 others
Phase 3
60 of 374
3 open now
Registered
263rd of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 23rd largest by enrollment of the 366 interventional ones that give a count, is one of 8 that started in 2018, is one of 60 in phase 3, and was the 263rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in subjects with HER2 positive early breast cancer.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms
  • HER2-positive Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer

Browse trials for

Keywords

  • trastuzumab
  • Herceptin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed HER 2 overexpressing invasive primary operable Stage II/IIIa breast cancer (AJCC version 7 staging criteria).
  • Available tumor tissue for central review of status.
  • Planned surgical resection of breast tumor.
  • Planned chemotherapy.
  • Documentation of HER2 gene amplification or overexpression.
  • Ipsilateral, measurable tumor longest diameter > 2 cm.
  • Known estrogen receptor (ER) and progesterone receptor (PR) hormone status (may be performed during screening).
  • performance status of 0 or 1.
  • Adequate bone marrow, hepatic and renal functions.
  • (LVEF) ≥ 50% or within institutional normal limits, measured by echocardiography or MUGA scan.
  • Effective as defined by protocol.

Key Exclusion Criteria:

  • therapy within 2 months of first dose of study drug.
  • Bilateral breast cancer.
  • Inflammatory breast cancer
  • .
  • Prior chemotherapy, biologic therapy, radiation or surgery for any active , including breast cancer.
  • Cardiac insufficiency, myocardial infarction, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident, unstable angina pectoris, uncontrolled arrhythmia or pulmonary embolus within the previous 12 months prior to 1st administration of study drug.
  • active infection, poorly controlled diabetes mellitus and/or uncontrolled hypertension.
  • Major surgery, significant traumatic injury, radiation therapy and/or grade 3 hemorrhage within 4 weeks of 1st administration of study drug.
  • Pre-existing clinically significant Grade 2 peripheral neuropathy.
  • Malignancy within the last 5 years (except squamous/basal cell carcinoma of the skin, cervical carcinoma in situ and superficial bladder cancer).
  • Severe dyspnea at rest requiring oxygen therapy.
  • Known positive , acute or chronic active infection with or .
  • Current pregnancy or breastfeeding.
  • Pre-existing thyroid abnormality with thyroid function that cannot be maintained in normal range despite optimal therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
809 participants (actual)

Study arms

  • Experimental
    TX05 (trastuzumab)

    • Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles Followed by: • IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles

    Biological: TX05 (trastuzumab) · Drug: Paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide

  • Active comparator
    Herceptin®

    • Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles Followed by: • IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles

    Biological: Herceptin® · Drug: Paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide

Interventions

  • 8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)

  • BiologicalHerceptin®

    8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)

  • 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)

    Also known as: Ribotax

  • 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)

  • 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)

    Pathologic complete response was determined by central review and defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0).

    Time frame: 3-7 weeks following last dose of study treatment

Secondary outcomes

  1. Objective Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (ORR) = CR + PR.

    Time frame: End of Treatment (Week 24) or Early Termination Visit

07

Results

Posted Jan 14, 2022

Participant flow

A total of 809 subjects were randomized to the study. Of these, 806 subjects initiated protocol treatment.

Participant flow — Overall Study
MilestoneTX05 (Trastuzumab)Herceptin®
Started404405
Subjects treated401405
Subjects receiving tx05 or herceptin394400
Completed393393
Not completed1112
Withdrew: Subjects randomized that did not treat30
Withdrew: Subjects who randomized and treated but drop prior to cycle 575
Withdrew: Discontinued treatment after cycle 5 due to adverse event01
Withdrew: Discontinued treatment after cycle 5 due to death01
Withdrew: Discontinued treatment after cycle 5 due to consent withdrawn02
Withdrew: Discontinued treatment after cycle 5 due to covid-1901
Withdrew: Discontinued treatment after cycle 5 due to other (subject decision)12

Outcome measures

PrimaryProportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)

Pathologic complete response was determined by central review and defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0).

Time frame:
3-7 weeks following last dose of study treatment
Reported as:
Number · participants
Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)
participantsTX05 (Trastuzumab)Herceptin®
Subjects who do not Meet pCR Criteria172185
Subjects Meeting pCR Criteria164153
Statistical analysis
  • TX05 (Trastuzumab) vs Herceptin® · Risk ratio (rr): 1.0783 · 95% CI 0.9185 to 1.2659
SecondaryObjective Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (ORR) = CR + PR.

Time frame:
End of Treatment (Week 24) or Early Termination Visit
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsTX05 (Trastuzumab)Herceptin®
Objective Response Rate (ORR)332340

Adverse events

Collected over Serious Adverse Events were recorded from Screening, while Adverse Events were recorded from Day 1 (Week 0) of Cycle 1 of study treatment through End of Treatment (Week 24).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TX05 (Trastuzumab)0/394 (0%)11/394 (2.8%)246/394 (62.4%)
Herceptin®1/400 (0.3%)9/400 (2.3%)250/400 (62.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTX05 (Trastuzumab)Herceptin®
Drug-induced liver injuryHepatobiliary disorders2/3940/400
Urinary Tract InfectionInfections and infestations2/3940/400
Acute Kidney InjuryRenal and urinary disorders0/3942/400
Febrile NeutropeniaBlood and lymphatic system disorders1/3941/400
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders1/3940/400
Diabetic Metabolic DecompensationMetabolism and nutrition disorders1/3940/400
Vaginal HemorrhageReproductive system and breast disorders1/3940/400
ThrombophlebitisVascular disorders1/3940/400
PneumoniaInfections and infestations1/3941/400
Cardiac Failure AcuteCardiac disorders1/3940/400
Most frequent other events
Most frequent other events
EventTX05 (Trastuzumab)Herceptin®
ArthralgiaMusculoskeletal and connective tissue disorders50/39442/400
MyalgiaMusculoskeletal and connective tissue disorders45/39439/400
AstheniaGeneral disorders30/39440/400
Peripheral Sensory NeuropathyNervous system disorders33/39430/400
Neuropathy PeripheralNervous system disorders16/39433/400
NauseaGastrointestinal disorders27/39431/400
Alanine Aminotransferase IncreasedInvestigations27/39426/400
AnemiaBlood and lymphatic system disorders26/39425/400
Aspartate Aminotransferase IncreasedInvestigations19/39412/400

Baseline characteristics

Safety population/The modified intent-to-treat (mITT) population includes all subjects who are randomized into the study and receive at least 1 dose of TX05 or Herceptin.

Age, Continuous
Age, Continuous(years)TX05 (Trastuzumab)Herceptin®Total
Mean54.2 ± 11.8053.4 ± 10.8353.8 ± 11.32
Sex: Female, Male
Sex: Female, Male(Participants)TX05 (Trastuzumab)Herceptin®Total
Female394400794
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TX05 (Trastuzumab)Herceptin®Total
Hispanic or Latino6971140
Not Hispanic or Latino325328653
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TX05 (Trastuzumab)Herceptin®Total
American Indian or Alaska Native151429
Asian6472136
Native Hawaiian or Other Pacific Islander000
Black or African American011
White292286578
More than one race000
Unknown or Not Reported232750
Hormone Receptor Status
Hormone Receptor Status(Participants)TX05 (Trastuzumab)Herceptin®Total
Positive253254507
Negative141146287
ECOG
ECOG(Participants)TX05 (Trastuzumab)Herceptin®Total
Grade 0316305621
Grade 17895173
Tumor Stage
Tumor Stage(Participants)TX05 (Trastuzumab)Herceptin®Total
IIA142141283
IIB169173342
IIIA8386169
08

Study locations

146 sites
  • Tanvex Investigational Site 1008
    Lesnoy, Minsk Region 223040, Belarus
  • Tanvex Investigational Site 1007
    Babruysk, Mogilev Region 213825, Belarus
  • Tanvex Investigational Site 1003
    Gomel, 246012, Belarus
  • Tanvex Investigational Site 1006
    Grodno, 230017, Belarus
  • Tanvex Investigational Site 1002
    Minsk, 220013, Belarus
  • Tanvex Investigational Site 1005
    Mogilev, 2120018, Belarus
  • Tanvex Investigational Site 1001
    Vitebsk, 21008, Belarus
  • Tanvex Investigational Site 4001
    Temuco, 4810469, Chile
  • Tanvex Investigational Site 4002
    Viña Del Mar, 2520598, Chile
  • Tanvex Investigational Site 5006
    Batumi, 6000, Georgia
  • Tanvex Investigational Site 5002
    Batumi, 6010, Georgia
  • Tanvex Investigational Site 5003
    Tbilisi, 0144, Georgia
  • Tanvex Investigational Site 5001
    Tbilisi, 0159, Georgia
  • Tanvex Investigational Site 5005
    Tbilisi, 0159, Georgia
  • Tanvex Investigational Site 5012
    Tbilisi, 0159, Georgia
  • Tanvex Investigational Site 5013
    Tbilisi, 0177, Georgia
  • Tanvex Investigational Site 5004
    Tbilisi, 0179, Georgia
  • Tanvex Investigational Site 5010
    Tbilisi, 0186, Georgia
  • Tanvex Investigational Site 5011
    Tbilisi, 0186, Georgia
  • Tanvex Investigational Site 5008
    Tbilisi, 112, Georgia
  • Tanvex Investigational Site 5009
    Tbilisi, 131, Georgia
  • Tanvex Investigational Site 5007
    Tbilisi, 141, Georgia
  • Tanvex Investigational Site 6003
    Budapest, 1122, Hungary
  • Tanvex Investigational Site 6007
    Budapest, 1122, Hungary
  • Tanvex Investigational Site 6005
    Debrecen, 4032, Hungary
  • Tanvex Investigational Site 6006
    Győr, 9024, Hungary
  • Tanvex Investigational Site 6004
    Miskolc, 3526, Hungary
  • Tanvex Investigational Site 6001
    Pécs, 7264, Hungary
  • Tanvex Investigational Site 7007
    Nashik, Maharashtra 422005, India
  • Tanvex Investigational Site 7015
    Pune, Maharashtra 411001, India
  • Tanvex Investigational Site 7003
    Pune, Maharashtra 411004, India
  • Tanvex Investigational Site 7004
    Pune, Maharashtra 411004, India
  • Tanvex Investigational Site 7002
    Bīkaner, Rajasthan 334003, India
  • Tanvex Investigational Site 7010
    Madurai, Tamil Nadu 625107, India
  • Tanvex Invesitgational Site 7033
    Ahmedabad, 380016, India
  • Tanvex Investigational Site 7019
    Bangalore, 560027, India
  • Tanvex Investigational Site 7037
    Bangalore, 560072, India
  • Tanvex Investigational Site 7022
    Belgaum, 590010, India
  • Tanvex Investigational Site 7034
    Chandigarh, 160012, India
  • Tanvex Investigational Site 7013
    Coimbatore, 641037, India
  • Tanvex Investigational Site 7024
    Gurgaon, 122001, India
  • Tanvex Investigational Site 7045
    Hyderabad, 500004, India
  • Tanvex Investigational Site 7036
    Hyderabad, 500034, India
  • Tanvex Investigational Site 7009
    Jaipur, 302004, India
  • Tanvex Investigational Site 7039
    Kolkata, 700014, India
  • Tanvex Investigational Site 7040
    Kolkata, 700094, India
  • Tanvex Investigational Site 7006
    Kolkata, 700099, India
  • Tanvex Investigational Site 7005
    Lucknow, 226003, India
  • Tanvex Investigational Site 7012
    Manipala, 576104, India
  • Tanvex Investigational Site 7041
    Model Town, 141002, India
  • Tanvex Investigational Site 7031
    Naka, 422004, India
  • Tanvex Investigational Site 7001
    Nashik, 422002, India
  • Tanvex Investigational Site 7042
    Trichy, 620008, India
  • Tanvex Investigational Site 7018
    Vadodara, 390007, India
  • Tanvex Investigational Site 7017
    Vijayawada, 520002, India
  • Tanvex Investigational Site 2102
    Monterrey, Nuevo León 64000, Mexico
  • Tanvex Investigational Site 2117
    Aguascalientes, 20127, Mexico
  • Tanvex Investigational Site 2109
    Aguascalientes, 20234, Mexico
  • Tanvex Investigational Site 2116
    Cancun, 77506, Mexico
  • Tanvex Investigational Site 2111
    Ciudad de mexico, 06760, Mexico
  • Tanvex Investigational Site 2104
    Cuauhtemoc, 06100, Mexico
  • Tanvex Investigational Site 2114
    Cuauhtémoc, 06760, Mexico
  • Tanvex Investigational Site 2101
    Cuautitlán Izcalli, 54769, Mexico
  • Tanvex Investigational Site 2113
    Mexico, 06100, Mexico
  • Tanvex Investigational Site 2103
    Monterrey, 64320, Mexico
  • Tanvex Investigational Site 2106
    Oaxaca, 68000, Mexico
  • Tanvex Investigational Site 2112
    San Luis Potosí, 78200, Mexico
  • Tanvex Investigational Site 2110
    Tequisquiapan, 76750, Mexico
  • Tanvex Investigational Site 2108
    Zapopan, 45030, Mexico
  • Tanvex Investigational Site 1104
    Chiclayo, Lambayeque 14001, Peru
  • Tanvex Investigational Site 1112
    Lima Cercado, Lima 15082, Peru
  • Tanvex Investigational Site 1108
    San Borja, Lima 15036, Peru
  • Tanvex Investigational Site 1113
    San Borja, Lima 15036, Peru
  • Tanvex Investigational Site 1101
    Arequipa, 04001, Peru
  • Tanvex Investigational Site 1107
    Arequipa, 04001, Peru
  • Tanvex Investigational Site 1110
    Lima, 15046, Peru
  • Tanvex Investigational Site 1105
    San Isidro, 15036, Peru
  • Tanvex Investigational Site 1102
    San Isidro, 15073, Peru
  • Tanvex Investigational Site 1109
    Surquillo, 15038, Peru
  • Tanvex Investigational Site 1103
    Trujillo, 13001, Peru
  • Tanvex Investigational Site 1210
    Santo Tomas, Batangas 4234, Philippines
  • Tanvex Investigational Site 1203
    Cebu City, Cebu 6000, Philippines
  • Tanvex Investigational Site 1204
    Cebu City, Cebu 6000, Philippines
  • Tanvex Investigational Site 1211
    Cebu City, Cebu 6000, Philippines
  • Tanvex Investigational Site 1208
    Quezon City, Manila 1110, Philippines
  • Tanvex Investigational Site 1207
    Manila, Metro Manila 1000, Philippines
  • Tanvex Investigational Site 1206
    Bacolod City, Negros Occidental 6100, Philippines
  • Tanvex Investigational Site 1212
    Davao City, 8000, Philippines
  • Tanvex Investigational Site 1214
    Makati City, 1229, Philippines
  • Tanvex Investigational Site 1201
    Manila, 1000, Philippines
  • Tanvex Investigational Site 1209
    Quezon City, 1101, Philippines
  • Tanvex Investigational Site 1213
    Quezon City, 1102, Philippines
  • Tanvex Investigational Site 1529
    Krasnodar, Krasnodar Region 350040, Russian Federation
  • Tanvex Investigational Site 1513
    Sochi, Krasnodar Region 354057, Russian Federation
  • Tanvex Investigational Site 1509
    Omsk, Omsk Region 644013, Russian Federation
  • Tanvex Investigational Site 1522
    Ufa, Republic Of Bashkortostan 450054, Russian Federation
  • Tanvex Investigational Site 1510
    Pushkin, Saint Petersburg 196603, Russian Federation
  • Tanvex Investigational Site 1511
    Novosibirsk, Siberia 630099, Russian Federation
  • Tanvex Investigational Site 1519
    Pyatigorsk, Stavropol Region 357502, Russian Federation
  • Tanvex Investigational Site 1518
    Tomsk, Tomsk Region 634050, Russian Federation

Showing the first 100 of 146 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2020, 28 months.

Results were first posted in Jan 2022, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Jun 14, 2018
StartActual
Jun 28, 2018
Primary completionActual
Nov 27, 2020
CompletionActual
Feb 4, 2021
Results first posted
Jan 14, 2022
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03556358
Lead sponsor
Tanvex BioPharma USA, Inc.
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Jun 28, 2018
Primary completion
Nov 27, 2020
Completion
Feb 4, 2021
Results posted
Jan 14, 2022
Last update
Jan 14, 2022

Study contacts

Bonnie Mills, PhD
study director · Tanvex BioPharma USA, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion